Page 84 - GPD-3-2

Gene & Protein in Disease Opportunities and challenges of HIF-1 in cancer

conditions. Int J Radiat Biol. 2020;96(8):1060-1067. 131. Wang B, Zhao Q, Zhang Y, et al. Targeting hypoxia in the
doi: 10.1080/09553002.2020.1770358 tumor microenvironment: A potential strategy to improve
cancer immunotherapy. J Exp Clin Cancer Res. 2021;40:24.
122. Habashy KJ, Mansour R, Moussalem C, Sawaya R,
Massaad MJ. Challenges in glioblastoma immunotherapy: doi: 10.1186/s13046-020-01820-7
Mechanisms of resistance and therapeutic approaches to 132. Food and Drug Administration. FDA Approves First Oral
overcome them. Br J Cancer. 2022;127(6):976-987. Treatment for Anemia Caused by Chronic Kidney Disease
doi: 10.1038/s41416-022-01864-w for Adults on Dialysis. Available from: https://www.fda.gov/
news-events/press-announcements/fda-approves-first-
123. Lequeux A, Noman MZ, Xiao M, et al. Targeting HIF-1 oral-treatment-anemia-caused-chronic-kidney-disease-
alpha transcriptional activity drives cytotoxic immune adults-dialysis [Last accessed on 2024 Apr 10].
effector cells into melanoma and improves combination
immunotherapy. Oncogene. 2021;40(28):4725-4735. 133. Ishii T, Tanaka T, Nangaku M. Profile of daprodustat in the
treatment of renal anemia due to chronic kidney disease.
doi: 10.1038/s41388-021-01846-x Ther Clin Risk Manag. 2021;17:155-163.
124. Halpin-Veszeleiova K, Hatfield SM. Oxygenation doi: 10.2147/tcrm.s293879
and A2AR blockade to eliminate hypoxia/HIF-1α-
adenosinergic immunosuppressive axis and improve cancer 134. Dhillon S. Daprodustat: First approval. Drugs.
immunotherapy. Curr Opin Pharmacol. 2020;53:84-90. 2020;80(14):1491-1497.
doi: 10.1016/j.coph.2020.07.005 doi: 10.1007/s40265-020-01384-y
125. Nakamura K, Smyth MJ. Targeting cancer‐related 135. Food and Drug Administration. FDA Approves Belzutifan
inflammation in the era of immunotherapy. Immunol Cell for Cancers Associated with von Hippel-Lindau Disease.
Biol. 2017;95(4):325-332. Available from: https://www.fda.gov/drugs/resources-
information-approved-drugs/fda-approves-belzutifan-
doi: 10.1038/icb.2016.126
cancers-associated-von-hippel-lindau-disease [Last
126. You L, Wu W, Wang X, et al. The role of hypoxia‐inducible factor accessed on 2024 Apr 10].
1 in tumor immune evasion. Med Res Rev. 2020;41(3):1622-1643.
136. Deeks ED. Belzutifan: First approval. Drugs. 2021;81:1921-1927.
doi: 10.1002/med.21771
doi: 10.1007/s40265-021-01606-x
127. Lin Q, Wang X, Hu Y. The opportunities and challenges in
immunotherapy: Insights from the regulation of PD-L1 in 137. Mortezaee K, Majidpoor J, Kharazinejad E. The impact
cancer cells. Cancer Lett. 2023;569:216318. of hypoxia on tumor-mediated bypassing anti-PD-(L)1
therapy. Biomed Pharmacother. 2023;162:114646.
doi: 10.1016/j.canlet.2023.216318
doi: 10.1016/j.biopha.2023.114646
128. Bailey CM, Liu Y, Liu M, et al. Targeting HIF-1α
abrogates PD-L1-mediated immune evasion in tumor 138. Anang V, Singh A, Kottarath SK, Verma C. Receptors of
microenvironment but promotes tolerance in normal immune cells mediates recognition for tumors. Prog Mol
tissues. J Clin Invest. 2022;132(9):e150846. Biol Transl Sci. 2023;194:219-267.
doi: 10.1172/JCI150846 doi: 10.1016/bs.pmbts.2022.09.009
129. Garziera M, Scarabel L, Toffoli G. Hypoxic modulation of 139. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The
HLA-G expression through the metabolic sensor HIF-1 in nature of myeloid-derived suppressor cells in the tumor
human cancer cells. J Immunol Res. 2017;2017:4587520. microenvironment. Trends Immunol. 2016;37(3):208-220.
doi: 10.1155/2017/4587520 doi: 10.1016/j.it.2016.01.004
130. Noman MZ, Hasmim M, Lequeux A, et al. Improving 140. Benoit A, Vogin G, Duhem C, Berchem G, Janji B. Lighting
cancer immunotherapy by targeting the hypoxic tumor up the fire in the microenvironment of cold tumors:
microenvironment: New opportunities and challenges. A major challenge to improve cancer immunotherapy.
Cells. 2019;8(9):1083. Cells. 2023;12(13):1787.
doi: 10.3390/cells8091083 doi: 10.3390/cells12131787

Volume 3 Issue 2 (2024) 17 doi: 10.36922/gpd.3431